RFL

Rafael Holdings, Inc. is a biotechnology company. The Company holds interests in clinical and early-stage pharmaceutical companies, including a 100% interest in Cyclo Therapeutics, LLC, a biotechnology company focusing on developing its lead clinical candidate, Trappsol Cyclo, which is being evaluated in clinical trials, including an ongoing Phase III trial for the potential treatment of Niemann-Pick Disease Type C1 (NPC1), a rare, fatal, and progressive genetic disorder. It also holds an interest in LipoMedix Pharmaceuticals Ltd., a clinical-stage pharmaceutical company; Barer Institute Inc., a wholly owned preclinical cancer metabolism research operation, and an interest in Cornerstone Pharmaceuticals, Inc., a cancer metabolism-based therapeutics company. It holds an interest in Rafael Medical Devices, LLC, an orthopedic-focused medical device company developing instruments to advance minimally invasive surgeries, and a majority interest in Day Three Labs, Inc.

Wall Street analysts forecast RFL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for RFL is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Rafael Holdings Inc revenue for the last quarter amounts to 240.00K USD, increased 87.50 % YoY.

Rafael Holdings Inc. EPS for the last quarter amounts to -0.19 USD, decreased -48.65 % YoY.

Rafael Holdings Inc (RFL) has 21 emplpoyees as of December 15 2025.

Today RFL has the market capitalization of 75.57M USD.